Sponsor content
270 result(s) found, displaying 11 to 20
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for TREMFYA guselkumab 200 mg / 2 mL solution for injection, pre-filled pen (auto-injector).
-
Australian public assessment report (AusPar)Lazcluze (lazertinib) in combination with amivantamab is indicated for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations.
-
Sep-2025Prescription medicine evaluationActive ingredient: ibrutinib.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for LAZCLUZE lazertinib 240 mg film-coated tablets bottle.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for LAZCLUZE lazertinib 240 mg film-coated tablets blister pack.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for LAZCLUZE lazertinib 80 mg film-coated tablets bottle.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for LAZCLUZE lazertinib 80 mg film-coated tablets blister pack.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for DARZALEX daratumumab 100 mg/5 mL concentrated solution for infusion vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for DARZALEX daratumumab 400 mg/20 mL concentrated solution for infusion vial.
-